Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct 21;44(40):4284-4287.
doi: 10.1093/eurheartj/ehad292.

A randomized controlled trial of eplerenone in asymptomatic phospholamban p.Arg14del carriers

Remco de Brouwer  1   2 , Wouter P Te Rijdt  1   2   3 , Edgar T Hoorntje  2   4 , Ahmad Amin  5   6 , Folkert W Asselbergs  5   6   7   8 , Moniek G P J Cox  1 , Jeroen F van der Heijden  7   9 , Hans Hillege  1 , Jacco C Karper  1 , Belend Mahmoud  1 , Peter van der Meer  1 , Anton Oomen  10 , Anneline S J M Te Riele  7 , Herman H W Silljé  1 , Hanno L Tan  2   5   6 , Jan Peter van Tintelen  2   11 , Dirk J van Veldhuisen  1 , Berend Daan Westenbrink  1 , Ans C P Wiesfeld  1 , Tineke P Willems  12 , Paul A van der Zwaag  4 , Arthur A M Wilde  5   6 , Rudolf A de Boer  1   13 , Maarten P van den Berg  1
Affiliations

A randomized controlled trial of eplerenone in asymptomatic phospholamban p.Arg14del carriers

Remco de Brouwer et al. Eur Heart J. .
No abstract available

Keywords: Cardiomyopathy; Eplerenone; Fibrosis; Heart failure; Phospholamban; Randomized clinical trial.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: R.A.d.B. is president-elect of the Dutch Cardiac Society (NVVC), member of the Executive Committee of the DELIVER-trial and has received grants from AstraZeneca, Abbott, Boehringer Ingelheim, Cardior Pharmaceuticals GmbH, Ionis Pharmaceuticals, Inc., Novo Nordisk, and Roche in the last 36 months. R.A.d.B. has received payment or honoraria from Abbott, AstraZeneca, Bayer, Bristol Myers Squibb, Novartis, and Roche in the last 36 months. J.P.v.T. has received consulting fees from StrideBio in the last 36 months. A.A.M.W. has received grants from the Dutch Heart Foundation and consulting fees from LQT Therapeutics and ARMGO in the last 36 months. A.A.M.W. additionally is a member of the advisory board of the Leap Trial.

References

    1. van der Zwaag PA, van Rijsingen IAW, Asimaki A, Jongbloed JDH, van Veldhuisen DJ, Wiesfeld ACP, et al. . Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy. Eur J Heart Fail 2012;14:1199–1207. 10.1093/eurjhf/hfs119 - DOI - PMC - PubMed
    1. van Rijsingen IAW, van der Zwaag PA, Groeneweg JA, Nannenberg EA, Jongbloed JDH, Zwinderman AH, et al. . Outcome in phospholamban R14del carriers: results of a large multicentre cohort study. Circ Cardiovasc Genet 2014;7:455–465. 10.1161/CIRCGENETICS.113.000374 - DOI - PubMed
    1. Eijgenraam TR, Boukens BJ, Boogerd CJ, Schouten EM, van de Kolk CWA, Stege NM, et al. . The phospholamban p.(Arg14del) pathogenic variant leads to cardiomyopathy with heart failure and is unresponsive to standard heart failure therapy. Sci Rep 2020;10:9819. 10.1038/s41598-020-66656-9 - DOI - PMC - PubMed
    1. Eijgenraam TR, Boogerd CJ, Stege NM, Oliveira Nunes Teixeira V, Dokter MM, Schmidt LE, et al. . Protein aggregation is an early manifestation of phospholamban p.(Arg14del)-related cardiomyopathy: development of PLN-R14del-related cardiomyopathy. Circ Heart Fail 2021;14:e008532. 10.1161/CIRCHEARTFAILURE.121.008532 - DOI - PMC - PubMed
    1. Zannad F, Alla F, Dousset B, Perez A, Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure. Circulation 2000;102:2700–2706. 10.1161/01.CIR.102.22.2700 - DOI - PubMed